Patient characteristics and overall survival in patients with post-docetaxel metastatic castration-resistant prostate cancer in the community setting
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1559-131X
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
Patient characteristics and overall survival in patients with post-docetaxel metastatic castration-resistant prostate cancer in the community setting ; volume:34 ; number:9 ; day:10 ; month:8 ; year:2017 ; pages:1-10 ; date:9.2017
Medical oncology ; 34, Heft 9 (10.8.2017), 1-10, 9.2017
- Schlagwort
-
Krebs
Onkologie
- Urheber
-
Oh, William K.
- Beteiligte Personen und Organisationen
-
Miao, Raymond
Vekeman, Francis
Sung, Jennifer
Cheng, Wendy Y.
Gauthier-Loiselle, Marjolaine
Dhawan, Ravinder
Duh, Mei Sheng
SpringerLink (Online service)
- DOI
-
10.1007/s12032-017-1014-2
- URN
-
urn:nbn:de:1111-2017110822838
- Rechteinformation
-
Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
15.08.2025, 07:35 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Oh, William K.
- Miao, Raymond
- Vekeman, Francis
- Sung, Jennifer
- Cheng, Wendy Y.
- Gauthier-Loiselle, Marjolaine
- Dhawan, Ravinder
- Duh, Mei Sheng
- SpringerLink (Online service)
Ähnliche Objekte (12)
Safety and survival of docetaxel and cabazitaxel in metastatic castration-resistant prostate cancer
Comparison of docetaxel pharmacokinetics between castration-resistant and hormone-sensitive metastatic prostate cancer patients
Multiple Docetaxel Retreatments Without Prednisone for Metastatic Castration-Resistant Prostate Cancer in the Docetaxel-Only Era: Effects on PSA Kinetics and Survival
Ureter metastatic castration-resistant prostate cancer: a case report
Adjusting Overall Survival Estimates after Treatment Switching: a Case Study in Metastatic Castration-Resistant Prostate Cancer
Prolonged PSA stabilization and overall survival following sipuleucel-T monotherapy in metastatic castration-resistant prostate cancer patients
JMJD2A participates in cytoskeletal remodeling to regulate castration-resistant prostate cancer docetaxel resistance
Physician preferences for non-metastatic castration-resistant prostate cancer treatment
Radioligand therapy of metastatic castration-resistant prostate cancer: current approaches
Low hemoglobin and PSA kinetics are prognostic factors of overall survival in metastatic castration-resistant prostate cancer patients
Longitudinal CTCs gene expression analysis on metastatic castration-resistant prostate cancer patients treated with docetaxel reveals new potential prognosis markers
External validation of risk classification in patients with docetaxel-treated castration-resistant prostate cancer
Safety and survival of docetaxel and cabazitaxel in metastatic castration-resistant prostate cancer
Comparison of docetaxel pharmacokinetics between castration-resistant and hormone-sensitive metastatic prostate cancer patients
Multiple Docetaxel Retreatments Without Prednisone for Metastatic Castration-Resistant Prostate Cancer in the Docetaxel-Only Era: Effects on PSA Kinetics and Survival
Ureter metastatic castration-resistant prostate cancer: a case report
Adjusting Overall Survival Estimates after Treatment Switching: a Case Study in Metastatic Castration-Resistant Prostate Cancer
Prolonged PSA stabilization and overall survival following sipuleucel-T monotherapy in metastatic castration-resistant prostate cancer patients
JMJD2A participates in cytoskeletal remodeling to regulate castration-resistant prostate cancer docetaxel resistance
Physician preferences for non-metastatic castration-resistant prostate cancer treatment
Radioligand therapy of metastatic castration-resistant prostate cancer: current approaches
Low hemoglobin and PSA kinetics are prognostic factors of overall survival in metastatic castration-resistant prostate cancer patients
Longitudinal CTCs gene expression analysis on metastatic castration-resistant prostate cancer patients treated with docetaxel reveals new potential prognosis markers
External validation of risk classification in patients with docetaxel-treated castration-resistant prostate cancer
Safety and survival of docetaxel and cabazitaxel in metastatic castration-resistant prostate cancer
Comparison of docetaxel pharmacokinetics between castration-resistant and hormone-sensitive metastatic prostate cancer patients
Multiple Docetaxel Retreatments Without Prednisone for Metastatic Castration-Resistant Prostate Cancer in the Docetaxel-Only Era: Effects on PSA Kinetics and Survival
Ureter metastatic castration-resistant prostate cancer: a case report
Adjusting Overall Survival Estimates after Treatment Switching: a Case Study in Metastatic Castration-Resistant Prostate Cancer
Prolonged PSA stabilization and overall survival following sipuleucel-T monotherapy in metastatic castration-resistant prostate cancer patients
JMJD2A participates in cytoskeletal remodeling to regulate castration-resistant prostate cancer docetaxel resistance
Physician preferences for non-metastatic castration-resistant prostate cancer treatment
Radioligand therapy of metastatic castration-resistant prostate cancer: current approaches
Low hemoglobin and PSA kinetics are prognostic factors of overall survival in metastatic castration-resistant prostate cancer patients
Longitudinal CTCs gene expression analysis on metastatic castration-resistant prostate cancer patients treated with docetaxel reveals new potential prognosis markers